Loading...
•
Dec 31, 2023
Ultragenyx Q4 2023 Earnings Report
Ultragenyx reported Q4 2023 financial results, demonstrating revenue growth and pipeline advancements.
Key Takeaways
Ultragenyx reported a 23% increase in total revenue for Q4 2023, reaching $127 million. The company saw growth in Crysvita and Dojolvi sales. They are focused on advancing their Phase 3 programs and executing commercial product launches.
Total revenue for Q4 2023 was $127 million, a 23% increase compared to Q4 2022.
Crysvita revenue for Q4 2023 was $94 million, a 17% increase compared to Q4 2022, including significant growth in Latin America and Turkey.
Dojolvi revenue for Q4 2023 was $23 million, a 42% increase compared to Q4 2022.
Net loss for Q4 2023 was $123 million, or $1.52 per share, compared to a net loss of $152 million, or $2.16 per share, for Q4 2022.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Revenue by Segment
Crysvita Revenue
CapyFin.comDojolvi Revenue
CapyFin.comEvkeeza Revenue
CapyFin.comMepsevii Revenue
CapyFin.com Forward Guidance
Ultragenyx reaffirms its financial guidance for the full year 2024.
Positive Outlook
- Total revenue is expected to be in the range of $500 million to $530 million.
- Crysvita revenue is expected to be in the range of $375 million to $400 million, including product sales in Latin America and Turkey, royalties in Europe, and royalties in North America.
- Dojolvi revenue is expected to be in the range of $75 million to $80 million.
- Net cash used in operations is expected to be less than $400 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income